Alkermes Plc Stock Price, News & Analysis

Alkermes (Nasdaq: ALKS) announced the launch of its 8th Annual Pathways Research Awards program, offering grants of up to $100,000 per project to early-career investigators in neuroscience. The program will accept applications from September 15 through December 15, 2025.

This year's program expands its focus to include research on sleep and circadian disturbances associated with bipolar I disorder and schizophrenia. Since its inception in 2018, the program has provided $2.7 million in funding to 27 researchers across the United States. Eligible applicants must be M.D.s, Ph.D.s, or equivalent, within five years of initial academic appointment or current post-doctoral fellows at U.S. institutions.

Alkermes (Nasdaq: ALKS) announced positive results from the Vibrance-1 phase 2 study of alixorexton in narcolepsy type 1 (NT1) patients at World Sleep Congress 2025. The study demonstrated clinically meaningful and statistically significant improvements in wakefulness, cognition, and fatigue across all tested doses (4mg, 6mg, and 8mg).

Key findings include: All dose groups achieved normative wakefulness with mean sleep latency of 24-28 minutes, significant improvements in the Epworth Sleepiness Scale, and over 40% of patients at higher doses achieved complete cataplexy reduction. The drug was generally well-tolerated with no serious adverse events reported.

Based on these results, Alkermes plans to initiate a global phase 3 program in Q1 2026. Additional phase 2 studies (Vibrance-2 and Vibrance-3) are ongoing for narcolepsy type 2 and idiopathic hypersomnia.

Alkermes (Nasdaq: ALKS) will present detailed results from its Vibrance-1 Phase 2 study of alixorexton (formerly ALKS 2680) for narcolepsy type 1 (NT1) at the World Sleep Congress 2025 in Singapore. The study data will be shared through three oral presentations focusing on safety, efficacy, and patient-reported outcomes.

The presentations will detail improvements in fatigue, cognitive impairment, and other symptoms in NT1 patients. Alixorexton is a novel, oral, selective orexin 2 receptor (OX2R) agonist being developed as a once-daily treatment for NT1, narcolepsy type 2, and idiopathic hypersomnia. The company will host an investor webcast on September 8, 2025, at 8:00 a.m. ET to discuss the findings.

Alkermes (NASDAQ:ALKS) reported strong Q2 2025 financial results with total revenues of $390.7 million and GAAP net income of $87.1 million ($0.52 per share). The company demonstrated robust performance across its proprietary product portfolio, with LYBALVI reaching $84.3 million (18% growth), ARISTADA at $101.3 million (18% growth), and VIVITROL at $121.7 million (9% growth).

The company maintained a strong balance sheet with $1.05 billion in cash and investments as of June 30, 2025, up from $916.2 million in Q1. Additionally, Alkermes announced positive topline results from its Vibrance-1 phase 2 study of alixorexton in narcolepsy type 1, with detailed results to be presented at the upcoming World Sleep Congress.

The company reiterated its 2025 financial expectations and continues to demonstrate solid profitability with Adjusted EBITDA of $126.5 million for the quarter.

Alkermes (NASDAQ:ALKS) announced positive topline results from its Vibrance-1 Phase 2 study of alixorexton in patients with narcolepsy type 1 (NT1). The study met its primary endpoint, demonstrating statistically significant improvements in wakefulness across all tested doses (4mg, 6mg, and 8mg) compared to placebo.

The once-daily oral treatment showed clinically meaningful improvements in multiple areas: normalized wakefulness (MWT), reduced excessive daytime sleepiness (ESS), and improved patient-reported outcomes related to disease severity, fatigue, and cognition. The drug was generally well-tolerated, with no serious adverse events reported. Over 95% of participants continued into the seven-week open-label extension.

Based on these positive results, Alkermes plans to advance alixorexton to Phase 3 development for NT1. Detailed results will be presented at the World Sleep Congress in September 2025.

Alkermes (Nasdaq: ALKS), a global biopharmaceutical company focused on neuroscience, has scheduled its second quarter 2025 financial results conference call and webcast for July 29, 2025, at 8:00 a.m. ET.

The company specializes in developing treatments for alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. Their pipeline includes clinical and preclinical candidates for neurological disorders such as narcolepsy and idiopathic hypersomnia. Alkermes maintains operations across Ireland, Massachusetts, and Ohio.

Alkermes plc (ALKS) announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference, with management scheduled for a fireside chat presentation on June 9, 2025, at 10:00 a.m. EDT. The presentation will be accessible via webcast on the company's website under the Investors tab and will remain archived for 14 days. Alkermes is a global biopharmaceutical company focused on neuroscience, with commercial products targeting alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. The company maintains a pipeline of clinical and preclinical candidates for neurological disorders, including narcolepsy and idiopathic hypersomnia, with operations across Ireland, Massachusetts, and Ohio.

Alkermes (ALKS) presented research findings from its psychiatry portfolio at multiple scientific conferences during spring 2025, focusing on its products LYBALVI and ARISTADA. Key presentations included analyses of LYBALVI's long-term safety study, examining lipid and glycemic profiles across patient subgroups over four years of treatment. The company shared data at major conferences including AAPP, NEI Spring Congress, ISPOR, APA, ASCP, and Psych Congress Elevate. Notable research included evaluations of LYBALVI's effects on schizophrenia symptoms and ARISTADA's efficacy in treating schizophrenia. The presentations demonstrated Alkermes' commitment to advancing psychiatric care and contributing to scientific evidence in treating schizophrenia and bipolar I disorder.

Alkermes (ALKS) will present new research on ALKS 2680, its novel oral orexin 2 receptor agonist, at SLEEP 2025 conference. The company will showcase eight posters and two oral presentations, including key findings from Phase 1 studies. ALKS 2680 is in phase 2 development for narcolepsy type 1, type 2, and idiopathic hypersomnia. Notable results include: - Statistically significant wake-associated qEEG profile vs placebo - Well-tolerated single doses with significant improvements in mean sleep latency - No cardiac safety concerns in healthy volunteers - Phase 1b study showed positive results across all tested doses The company is currently conducting Phase 2 Vibrance Studies and expects to share topline results from Vibrance-1 in early Q3. The presentations will also include research on the clinical, economic, and humanistic burden of narcolepsy, along with findings from patient interviews on idiopathic hypersomnia.